Collegium Pharmaceutical, Inc.

Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2024 earnings conference call. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note that this conference call is being recorded. I'll now turn the call over to Christopher James, Vice President of Investor Relations at Collegium. Thank you.

You may begin. Welcome to Collegium Pharmaceuticals' second quarter 2024 earnings conference call. I'm joined today by Mike Heffernan, our interim president and chief executive officer, founder and chairman, Colleen Tupper, our chief financial officer, and Scott Dreyer, our chief commercial officer. Before we begin today's call, we want to remind participants that none of the information presented today is intended to be promotional and that any forward-looking statements made today are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. You will caution that such forward-looking statements involve risks and uncertainties, including and without limitation, the risk that we may not be able to successfully commercialize our products, that we may incur significant expense in doing so, that we may not prevail in current or future litigation pertaining to our business. Risk related to our ability to complete the acquisition of Iron Shore Therapeutics on the proposed terms and schedule or at all. Risk related to our ability to realize the anticipated benefits and synergies of the proposed acquisition of IronShore. The risk that the business will not be integrated successfully. Risk related to negative effects of this announcement or the consummation of proposed acquisition on the market price of our common stock and or operating results. And risk related to future opportunities and plans for IronShore. These risks and other risks of the company are detailed in the company's periodic reports filed with the Securities and Exchange Commission. Our future results may differ materially from our current expectations discussed today. Our earnings press release and this call will include discussion of certain non-GAAP information. You can find our earnings press release, including relevant non-GAAP reconciliations, on our corporate website at collegianpharma.com. I will now turn the call over to our Chairman, Interim President, and CEO, Mike Heffernan.

Thank you, Chris. Good afternoon, and thank you everyone for joining the call. Today, we will discuss Collegium's financial performance during the second quarter and provide an update on our progress in 2024. At Collegium, we are focused on building a leading diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions while striving to do good as we do well. I'd like to recognize the Collegium team for their dedication to our mission and community impact, as well as their strong performance in support of our pain portfolio, in implementing our capital deployment strategy in the first half of the year. Our results this quarter and through the first half of the year reinforce Collegium's strong operational execution. We continue to generate robust operating cash flows and drive significant top and bottom line growth in our paying portfolio, including growing revenue 7% and adjusted even at 12% on a year-over-year basis in the second quarter. Through execution of the HCMA authorized generic agreement, And securing the six-month pediatric exclusivity extension for the Nusenta franchise, we are maximizing the value of this portfolio to 2025 and beyond. The strength of our pain business positions us to execute on the recently announced proposed acquisition of IronShore Therapeutics, including its commercial product to an APM, a central nervous system stimulant for the treatment of attention deficit hyperactivity disorder, or ADHD, in people six years of age and older. The IronShore acquisition meets all of our business development objectives. JoinAPM is a highly differentiated commercial asset that diversifies our portfolio, has significant revenue and growth potential, and exclusivity into the 2030s. JoinAPM is expected to generate net revenue in excess of $100 million in 2024, expands our commercial presence into ADHD, a large and growing market, and is poised to become the leading growth driver for Collegium. Once the acquisition closes, we will leverage our core competencies with respect to commercial execution and build on our proven track record of efficiently and successfully integrating commercial assets to build our portfolio. Importantly, the addition to an APM serves as a step forward in building another therapeutic area of focus for Collegium. We look forward to closing this transaction in the third quarter, welcoming the Orange Shore team to Collegium, and embracing Jordan APM as the newest part of our portfolio. For the second half of this year, we're focused on delivering our financial commitments by maximizing our pain business while closing and seamlessly integrating our proposed acquisition of Iron Shore Therapeutics. We are confident that we will achieve our 2024 financial commitments for the pain business, which along with the Jordan APM will set a solid foundation for 2025 and beyond. Additionally, our search for the next CEO to lead Collegium in this upcoming phase of growth is active and ongoing, and we look forward to sharing updates on this important process as they become available. Our strong executive team has the full trust of the board and will continue our focus on operational execution during this process. I'll now hand the call over to Colleen to discuss key business highlights and financials.